Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Chun‐Wai Mai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6532-184X; OpenAlex author ID A5034469290. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
18
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 13

  1. Catching pancreatic cancer early: Are we there yet? Co-author DOI 10.1016/j.jncc.2025.12.001↗
  2. Evolving Molecular Drug Targets in Pancreatic Cancer: An Updated Review. Co-author DOI 10.2174/0115680096481382261002063656↗
  3. Major dietary patterns in the United Kingdom Women's Cohort Study showed no evidence of prospective association with pancreatic cancer risk. Co-author DOI 10.1016/j.nutres.2023.07.007↗
  4. Vitamin E in the management of pancreatic cancer: A scoping review. Last author DOI 10.4251/wjgo.v15.i6.943↗
  5. Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy. First author DOI 10.3389/fphar.2022.903210↗
  6. Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic Cancer. Last author DOI 10.3390/cancers14153709↗
  7. Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. Last author DOI 10.3748/wjg.v28.i18.1934↗
  8. Co-encapsulation of gemcitabine and tocotrienols in nanovesicles enhanced efficacy in pancreatic cancer. First author DOI 10.2217/nnm-2020-0374↗
  9. Traditional and Novel Adiposity Indicators and Pancreatic Cancer Risk: Findings from the UK Women's Cohort Study. Co-author DOI 10.3390/cancers13051036↗
  10. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation. Last author DOI 10.1007/s00432-020-03274-y↗
  11. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Last author DOI 10.3390/cancers12071872↗
  12. The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12906-019-2663-9↗
  13. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10495-018-1459-6↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ling‐Wei Hii · 6 shared papers, 2018–2022 · strength 0.86
  2. Rhun Yian Koh · 2 shared papers, 2026 · strength 0.74
  3. Chee‐Onn Leong · 5 shared papers, 2018–2022 · strength 0.71
  4. Chin-King Looi · 2 shared papers, 2022–2026 · strength 0.55
  5. Aminath Rana Abdul Rasheed · 1 shared paper, 2026 · strength 0.39
  6. Wynne Sim · 2 shared papers, 2022 · strength 0.37
  7. Wei Ming Pang · 1 shared paper, 2026 · strength 0.36
  8. Sangeetha Shyam · 2 shared papers, 2021–2023 · strength 0.35
  9. Janet Elizabeth Cade · 2 shared papers, 2021–2023 · strength 0.35
  10. Li-Lian Gan · 2 shared papers, 2020–2022 · strength 0.31
  11. Sophia Ogechi Ekeuku · 1 shared paper, 2023 · strength 0.24
  12. Geetha Maniam · 1 shared paper, 2021 · strength 0.19
  13. Ju‐Yen Fu · 1 shared paper, 2021 · strength 0.19
  14. Alan Cheuk Keong Yaw · 1 shared paper, 2020 · strength 0.16
  15. Elaine Wan Ling Chan · 1 shared paper, 2020 · strength 0.16
  16. Hui Shan Liew · 1 shared paper, 2022 · strength 0.16
  17. May Lee Low · 1 shared paper, 2022 · strength 0.16
  18. Jia Lin Er · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.